Lymphocyte therapy of renal cell carcinoma.
During the past 20 years, there has been considerable interest in lymphocyte therapy as a treatment for renal cell carcinoma. There is no therapeutic role for B-lymphocyte therapy, but their products, monoclonal antibodies, now have widespread clinical applications. The major types of autologous lymphocyte therapy that have been explored in clinical trials are cytotoxic lymphokine-activated killer cells, which are natural killer cells and T-cells that have been stimulated in vitro by interleukin-2 or other similar cytokines; cytotoxic and noncytotoxic tumor infiltrating lymphocytes, which are T-cells derived from tumor tissue; other tumor antigen-stimulated T-lymphocytes derived from regional lymph nodes or peripheral blood; and noncytotoxic lymphocytes of the memory/helper phenotype. More recently, allogeneic immune therapy using nonmyeloablative hematopoietic stem cell transplant and/or donor lymphocyte therapy has also shown promise.
Dillman
Robert O
RO
Hoag Comprehensive Cancer Center, Newport Beach, CA 92658, USA. rdillman@hoaghospital.org
D000951:Antigens, Neoplasm / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007156:Immunologic Memory; D007167:Immunotherapy / Q000379:methods*; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy*; D007694:Killer Cells, Natural / Q000276:immunology*; D010641:Phenotype; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm